Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats

Gen Pharmacol. 1994 Jul;25(4):697-704. doi: 10.1016/0306-3623(94)90248-8.

Abstract

1. A 6-week gliclazide treatment improved left ventricular developed pressure and left ventricular end-diastolic pressure, left ventricular pressure-rate products in isolated working hearts from streptozotocin-induced diabetic rats. 2. Post-ischemic recovery in heart rate, left ventricular developed pressure, left ventricular end-diastolic pressure, left ventricular pressure-rate products and cardiac work were also shown in gliclazide-treated diabetic rats. 3. Gliclazide treatment did not modify the degree of insulinopenia and hyperglycemia, nor the myocardial energy metabolism during ischemia-reperfusion. 4. The results suggest that the gliclazide treatment has a cardioprotective effect on basal and post-ischemic cardiac functions of chronic diabetes.

MeSH terms

  • Adenosine Triphosphate / analysis
  • Animals
  • Diabetes Mellitus, Experimental / physiopathology*
  • Gliclazide / pharmacology*
  • Heart / drug effects*
  • Heart / physiopathology
  • Lactates / metabolism
  • Lactic Acid
  • Male
  • Myocardial Ischemia / physiopathology*
  • Myocardial Reperfusion
  • Rats
  • Rats, Sprague-Dawley
  • Streptozocin

Substances

  • Lactates
  • Lactic Acid
  • Streptozocin
  • Adenosine Triphosphate
  • Gliclazide